Indication intelligence, analysis and sector perception

Organovo (ONVO) Achieves liver disease and intestinal 3D bio-printed tissue models milestones - BUY

April 16, 2018 9:40am

Closed down -$0.04 and is up +$0.0 or +7.28% to $1.09

ONVO continues to map out a range of relevant conditions for creating NASH, including all components of the disease (fat accumulation, inflammation and fibrosis).

ONVO has achieved several breakthrough capabilities for its 3D bioprinted tissues.

At last week’s International Liver CongressTM, two posters were presented illustrating ONVO’s ability to create functional human liver tissue, produce a spectrum of NASH disease conditions, and then treat that disease successfully with a client’s development stage non-alcoholic steatohepatitis (“NASH”) drug.

These posters highlighted the performance of Organovo’s human liver model in the generation of a robust non-alcoholic fatty liver disease (“NAFLD”) and NASH phenotype, including the presence of ‘gold standard’ histopathologic features.

Organovo and Merck & Co. (MRK) also jointly published a peer-reviewed study describing the Company’s bioprinted human intestinal model, which exhibits compelling architecture, barrier and metabolic functions, while also being able to model key aspects of toxicity and inflammation.

BUY

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

1 hour 48 min ago
RegMed Investors (RMi) Closing Bell: hammered

10 hours 39 min ago
RegMed Investors’ (RMi) pre-open: expectation versus reality

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.